A Long-Term Study of Zasocitinib in Children and Teenagers With Plaque Psoriasis (NCT07250802)
A Phase 3, Randomized, Multicenter, Double-Blind, Placebo-Controlled Trial to Evaluate the Efficacy, Safety, Tolerability, and Pharmacokinetics of Zasocitinib in Pediatric Participants Aged 4 to Less Than 18 Years With Moderate-to-Severe Plaque Psoriasis
🩺 Plain-English Summary (8th-Grade Level)
The main aim of this study is to see how well the medicine zasocitinib works, how safe it is, and how children and teenagers aged 4 to under 18 with moderate-to-severe plaque psoriasis respond to it. The study will be done in 2 parts: Part A will include both children and teenagers, while part B will only include children. At first, only teenagers who meet the study rules can participate in this study. Children may only start to participate once enough information has been collected from other studies with zasocitinib. Participants in Part A will initially be assigned to receive either zasocitinib or placebo for the first 16 weeks of treatment, then all participants will receive zasocitinib through the end of the study. All participants in Part B will be assigned to receive treatment with zasocitinib throughout the study. Participants will be in the study for up to 4 years and 2 months (217 weeks), including up to 35 days for the screening period, 208 weeks of treatment (Part A and Part B) and a 4-week safety follow-up period. During the study, participants will visit their study site multiple times.
Who can join: Review the eligibility criteria below.
Location: Exalt Clinical Research — Chula Vista, California
Age range: 4 Years to 17 Years
🧪 Interventions in This Study
📋 "Do I Qualify?" — 1-Minute Self Screener
Instant ChecklistFull eligibility criteria are available on the official NIH protocol. View the criteria ↗
📍 All Participating Trial Locations (40 Sites)
Showing the first 25 of 40 sites.
- Exalt Clinical Research — Chula Vista, California
- First OC Dermatology Research Inc. — Fountain Valley, California
- Direct Helpers Medical Center — Hialeah, Florida
- Arlington Dermatology — Rolling Meadows, Illinois
- Apex Clinical Research Center, LLC — Canton, Ohio
- Wright State Physicians — Fairborn, Ohio
- Apex Clinical Research Center, LLC — Mayfield Heights, Ohio
- Medical University of South Carolina — Charleston, South Carolina
- UT Physicians Dermatology - Bellaire Station — Bellaire, Texas
- Texas Dermatology and Laser Specialists-San Antonio — San Antonio, Texas
- Medical College of Wisconsin — Milwaukee, Wisconsin
- Beijing Children Hospital, Capital Medical University — Beijing, Beijing Municipality
- Dermatology Hospital of Southern Medical University — Guangzhou, Guangdong
- Hunan Children's Hospital — Changsha, Hunan
- Hangzhou First People's Hospital — Hangzhou, Zhejiang
- Peking University Third Hospital — Beijing,
- Huashan Hospital Fudan University — Shanghai,
- Johann Wolfgang Goethe-Universität Frankfurt am Main — Frankfurt am Main, Hesse
- Fachklinik Bad Bentheim — Bad Bentheim, Lower Saxony
- Uniklinik Koln, Klinik fur Dermatologie und Venerologie — Cologne, North Rhine-Westphalia
- University Hospital of Muenster — Münster, North Rhine-Westphalia
- Universitätsklinikum Bonn — Bonn,
- Universitaetsmedizin der Johannes - Gutenberg Universitaet Mainz — Mainz,
- Presidio Ospedaliero Gaspare Rodolico — Catania, Sicily
- Universita Degli Studi Di Padova — Padova,
📞 Contact the Study Coordinator
Phone: (877) 825-3327
Email: medinfoUS@takeda.com
Coordinator details come directly from the registered NIH protocol. Confirm the study is still recruiting before traveling.
💰 Cost, Insurance & Patient Rights
- 100% Free Items: The investigational treatment and protocol-required procedures are supplied at zero cost by the sponsor.
- Routine Patient Care: Under federal law (ACA § 2709) and many state statutes, routine care costs are covered during participation.
- Voluntary Participation: You may withdraw at any time without affecting your standard medical care.
More studies in Plaque Psoriasis
- A Study of JNJ-77242113 in Adolescent and Adult Participants With Moderate to Severe Plaque Psoriasis — Phoenix, Arizona
- Dose Ranging Study of ORKA-001 in Patients With Moderate-to-Severe Plaque Psoriasis — Phoenix, Arizona
- A Study of TAK-279 in Participants With Moderate-to-Severe Plaque Psoriasis — Birmingham, Alabama
- Tapinarof for the Treatment of Plaque Psoriasis in Pediatric Subjects — Rogers, Arkansas
- Open-Label Extension Study to Evaluate the Long Term Safety and Efficacy of ESK-001 in Plaque Psoriasis — Birmingham, Alabama
- A Study of JNJ-77242113 for the Treatment of Participants With Moderate to Severe Plaque Psoriasis (ICONIC-ADVANCE 2) — Phoenix, Arizona
Explore by condition: All Plaque Psoriasis clinical trials
💡 How to Participate
- Check the checklist above to see if you may qualify.
- Contact the study coordinator using the phone/email above.
- Ask about the visit schedule, what is covered at no cost, and any travel support.
- Confirm with your own doctor before making a decision.